Cargando…

Correction to: Efficacy of single-site radiotherapy plus PD-1 inhibitors vs PD-1 inhibitors for oligometastatic non-small cell lung cancer

Detalles Bibliográficos
Autores principales:	Wang, Peiliang, Yin, Tianwen, Zhao, Kaikai, Yu, Jinming, Teng, Feifei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9015975/ https://www.ncbi.nlm.nih.gov/pubmed/34878604 http://dx.doi.org/10.1007/s00432-021-03877-z

Ejemplares similares

Efficacy of single-site radiotherapy plus PD-1 inhibitors vs PD-1 inhibitors for oligometastatic non-small cell lung cancer
por: Wang, Peiliang, et al.
Publicado: (2021)

Safety and Efficacy of Concurrent or Sequential Radiotherapy Plus (PD-1) Inhibitors in Oligometastatic Esophageal Cancer
por: Duan, Yanan, et al.
Publicado: (2023)

Efficacy and Safety of Anti-PD-1 Plus Anlotinib in Patients With Advanced Non–Small-Cell Lung Cancer After Previous Systemic Treatment Failure—A Retrospective Study
por: Wang, Peiliang, et al.
Publicado: (2021)

Optimum fractionation of radiation to combine PD‐1 blockade
por: Teng, Feifei, et al.
Publicado: (2023)

Safety of thoracic radiotherapy after PD‐(L)1 inhibitor treatment in patients with lung cancer
por: Chen, Yu, et al.
Publicado: (2021)

Toxicity Profile of Combining PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy in Non-Small Cell Lung Cancer: A Systematic Review
por: Li, Butuo, et al.
Publicado: (2021)

PD-1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in patients with advanced non-squamous non-small-cell lung cancer: a pooled analysis of three randomised trials
por: Meng, Xiangjiao, et al.
Publicado: (2022)

Radiation recall pneumonitis induced by PD-1/PD-L1 blockades: mechanisms and therapeutic implications
por: Teng, Feifei, et al.
Publicado: (2020)

The Research Progress of PD-1/PD-L1 Inhibitors Enhancing Radiotherapy Efficacy
por: Wen, Lu, et al.
Publicado: (2021)

PD-1/PD-L1 Inhibitor Plus Chemotherapy Versus PD-1/PD-L1 Inhibitor in Microsatellite Instability Gastrointestinal Cancers: A Multicenter Retrospective Study
por: Chen, Mifen, et al.
Publicado: (2023)

PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus regorafenib in patients with advanced hepatocellular carcinoma after failure of sorafenib
por: Xu, Yongkang, et al.
Publicado: (2022)

Correction: Effect of body tissue composition on the outcome of patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors
por: Makrakis, Dimitrios, et al.
Publicado: (2023)

Hepatic Arterial Infusion Chemotherapy Combined With PD-1 Inhibitors Plus Lenvatinib Versus PD-1 Inhibitors Plus Lenvatinib for Advanced Hepatocellular Carcinoma
por: Mei, Jie, et al.
Publicado: (2021)

Efficacy and Safety of Fruquintinib Plus PD-1 Inhibitors Versus Regorafenib Plus PD-1 Inhibitors in Refractory Microsatellite Stable Metastatic Colorectal Cancer
por: Sun, Liying, et al.
Publicado: (2021)

Efficacy and Safety of PD-1/PD-L1 Inhibitors Plus Chemotherapy Versus PD-1/PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer: A Network Analysis of Randomized Controlled Trials
por: Li, Xiang, et al.
Publicado: (2021)

Clinical Outcomes for PD-1 Inhibitor Plus Chemotherapy as Second-Line or Later Therapy Compared to PD-1/PD-L1 Inhibitor Alone in Advanced Non-small-cell Lung Cancer
por: Zhai, Xiaoyang, et al.
Publicado: (2020)

PD-1/L1 inhibitor plus chemotherapy in the treatment of sarcomas
por: Tian, Zhichao, et al.
Publicado: (2022)

Hepatotoxicity in patients with solid tumors treated with PD-1/PD-L1 inhibitors alone, PD-1/PD-L1 inhibitors plus chemotherapy, or chemotherapy alone: systematic review and meta-analysis
por: Guo, Xiaodi, et al.
Publicado: (2020)

Anti‐PD‐L1/TGF‐βR fusion protein (SHR‐1701) overcomes disrupted lymphocyte recovery‐induced resistance to PD‐1/PD‐L1 inhibitors in lung cancer
por: Cheng, Bo, et al.
Publicado: (2022)

Author Correction: Real-world evidence and clinical observations of the treatment of advanced non-small cell lung cancer with PD-1/PD-L1 inhibitors
por: Song, Peng, et al.
Publicado: (2020)

Transarterial Chemoembolization Combined With PD-1 Inhibitors Plus Lenvatinib Showed Improved Efficacy for Treatment of Unresectable Hepatocellular Carcinoma Compared With PD-1 Inhibitors Plus Lenvatinib
por: Wang, Jinfeng, et al.
Publicado: (2023)

Clinical impact of tumour burden on the efficacy of PD‐1/PD‐L1 inhibitors plus chemotherapy in non‐small‐cell lung cancer
por: Miyawaki, Taichi, et al.
Publicado: (2022)

Correction to: Randomized trial of First-Line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-Mutated Non-Small cell lung cancer
Publicado: (2023)

PD-1/PD-L1 inhibitors plus anti-angiogenic agents with or without chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy as second or later-line treatment for patients with advanced non-small cell lung cancer: A real-world retrospective cohort study
por: Chen, Shubin, et al.
Publicado: (2022)

In vitro characterization of a small molecule PD-1 inhibitor that targets the PD-l/PD-L1 interaction
por: Lu, Chih-Hao, et al.
Publicado: (2022)

PD-1/PD-L1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in first-line treatment for non-squamous non-small-cell lung cancer
por: Yu, Hui, et al.
Publicado: (2021)

Real‐world utilization of PD‐1/PD‐L1 inhibitors with palliative radiotherapy in patients with metastatic non‐small cell lung cancer
por: Zhou, Zi‐Chao, et al.
Publicado: (2022)

PD0325901, an ERK inhibitor, enhances the efficacy of PD-1 inhibitor in non-small cell lung carcinoma
por: Luo, Min, et al.
Publicado: (2021)

Efficacy and safety comparison of PD-1 inhibitors vs. PD-L1 inhibitors in extensive-stage small-cell lung cancer: a retrospective comparative cohort study
por: Yang, Guanghui, et al.
Publicado: (2022)

PD-1/PD-L1 Inhibitors in Cervical Cancer
por: Liu, Yuncong, et al.
Publicado: (2019)

Correction: Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naïve and PD-1 antibody-experienced patients with melanoma (MEL64)
Publicado: (2022)

Deep abscopal response to radiotherapy and anti-PD-1 in an oligometastatic melanoma patient with unfavorable pretreatment immune signature
por: Watanabe, Tsubasa, et al.
Publicado: (2020)

PD-1/PD-L1 blockades in non-small-cell lung cancer therapy
por: Jing, Wang, et al.
Publicado: (2016)

Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells
por: Skalniak, Lukasz, et al.
Publicado: (2017)

Molecular Mechanism of Small-Molecule Inhibitors in Blocking the PD-1/PD-L1 Pathway through PD-L1 Dimerization
por: Guo, Yan, et al.
Publicado: (2021)

Di-bromo-Based Small-Molecule Inhibitors of the PD-1/PD-L1 Immune Checkpoint
por: Konieczny, Magdalena, et al.
Publicado: (2020)

Tumor response as defined by iRECIST in gastrointestinal malignancies treated with PD-1 and PD-L1 inhibitors and correlation with survival
por: Xie, Peiyi, et al.
Publicado: (2021)

Effectiveness and safety of PD-1/PD-L1 inhibitors in the treatment of solid tumors: a systematic review and meta-analysis
por: Wang, Xiaohui, et al.
Publicado: (2017)

Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
por: Yi, Ming, et al.
Publicado: (2018)

Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma
por: Jelinek, Tomas, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_qopljvpivh33tm5tc9kt7o7evs